CTOs on the Move

American Clinical Solutions

www.acslabtest.com

 
American Clinical Solutions is a leading provider of urine drug confirmation services, offering accurate testing for both prescription and illicit narcotics using the most advanced equipment available. Medical facilities and other healthcare providers rely on American Clinical to help ensure patient safety and maximize the benefits of prescription medicine use. ACS employs a unique, proprietary testing method with enhanced detection ability and improved accuracy which means physicians and other health care providers can prescribe with confidence. In addition to detecting improper use of prescribed and illicit drugs, ACS testing method helps healthcare providers monitor the efficacy of prescription regimens and ...
  • Number of Employees: 10K-50K
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

American Clinical Solutions raised $10M on 06/23/2015

Similar Companies

Global Dosimetry Solutions (GDS)

Global Dosimetry Solutions, Inc. (GDS) is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Country Pines Retirement Home

Country Pines Retirement Home is a Clearfield, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The CE Solution

The CE Solution is a Syosset, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Indiana University Health Bloomington Hospital

Bloomington Hospital is dedicated to serving the entire community. We recognize that some of our patients may need assistance when communicating with physicians and staff. A number of services are available at no cost to patients by calling the Hospital

Furiex

Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.